- Home
- NVR vs PODD Comparison
NVR vs PODD Comparison
Compare NVR & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVR
- PODD
- Stock Information
- Founded
- NVR 1980
- PODD 2000
- Country
- NVR United States
- PODD United States
- Employees
- NVR N/A
- PODD N/A
- Industry
- NVR Homebuilding
- PODD Medical/Dental Instruments
- Sector
- NVR Consumer Discretionary
- PODD Health Care
- Exchange
- NVR Nasdaq
- PODD Nasdaq
- Market Cap
- NVR 22.2B
- PODD 22.1B
- IPO Year
- NVR N/A
- PODD 2007
- Fundamental
- Price
- NVR $7,702.79
- PODD $330.73
- Analyst Decision
- NVR Buy
- PODD Strong Buy
- Analyst Count
- NVR 4
- PODD 19
- Target Price
- NVR $8,250.00
- PODD $338.79
- AVG Volume (30 Days)
- NVR 21.2K
- PODD 558.2K
- Earning Date
- NVR 10-23-2025
- PODD 11-06-2025
- Dividend Yield
- NVR N/A
- PODD N/A
- EPS Growth
- NVR N/A
- PODD N/A
- EPS
- NVR 474.94
- PODD 3.32
- Revenue
- NVR $10,717,672,000.00
- PODD $2,359,500,000.00
- Revenue This Year
- NVR N/A
- PODD $29.18
- Revenue Next Year
- NVR N/A
- PODD $18.16
- P/E Ratio
- NVR $16.41
- PODD $99.00
- Revenue Growth
- NVR 5.86
- PODD 26.00
- 52 Week Low
- NVR $6,562.85
- PODD $226.50
- 52 Week High
- NVR $9,867.00
- PODD $353.50
- Technical
- Relative Strength Index (RSI)
- NVR 44.51
- PODD 59.44
- Support Level
- NVR $7,600.22
- PODD $312.05
- Resistance Level
- NVR $7,827.92
- PODD $322.58
- Average True Range (ATR)
- NVR 168.68
- PODD 7.64
- MACD
- NVR -2.14
- PODD 2.19
- Stochastic Oscillator
- NVR 34.28
- PODD 84.50
About NVR NVR Inc.
NVR Inc is a United States-based homebuilding company. It builds single-family detached homes, townhomes, and condominium buildings under three brands, Ryan Homes, NVHomes, and Heartland Homes. The company through its subsidiary also operates a mortgage banking and title services business. The homebuilding segment includes four geographic areas of the Mid-Atlantic, North East, Mid-East, and South East.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.